How do I determine the appropriate intravenous iron dose based on patient weight and iron studies (transferrin saturation and ferritin) for a dialysis patient?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 3, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

IV Iron Dosing for Dialysis Patients

For hemodialysis patients, administer 100-200 mg of IV iron monthly when ferritin ≤200 ng/mL or TSAT ≤20%, with the goal of maintaining ferritin 200-800 ng/mL and TSAT 20-40%. 1

Initiation Criteria

Start IV iron therapy when:

  • Ferritin ≤200 ng/mL, OR 2
  • TSAT ≤20% (even if ferritin is between 200-800 ng/mL, indicating functional iron deficiency) 1, 2

The TSAT <20% threshold has high sensitivity for diagnosing both absolute and functional iron deficiency in dialysis patients. 1

Dosing Strategy

Two evidence-based approaches exist:

High-Dose Proactive Regimen (Preferred)

  • 400 mg monthly (typically divided as 100 mg per dialysis session weekly) 3
  • Superior outcomes: 15% reduction in cardiovascular events and death (HR 0.85,95% CI 0.73-1.00, P=0.04 for superiority) 3
  • Reduces ESA requirements by approximately 9,000 IU monthly 3
  • Mean monthly dose achieved: 264 mg 3

Moderate-Dose Maintenance Regimen

  • 200 mg monthly reduces ESA dose by 26% compared to 100 mg monthly 4
  • 100 mg monthly results in 30% absolute iron deficiency rate vs. 10.5% with 200 mg 4
  • The 200 mg regimen has higher withholding rates (64% vs. 25%) but better iron repletion 4

Stopping Criteria

Hold IV iron when:

  • Ferritin ≥800 ng/mL AND TSAT ≥20%, OR 1, 5
  • TSAT ≥40% (regardless of ferritin level) 1, 5

Never exceed ferritin >800 ng/mL in routine practice, as this approaches iron overload territory. 5

Target Parameters

Maintain these levels:

  • Ferritin: 200-800 ng/mL 1, 2
  • TSAT: 20-40% 1
  • Hemoglobin: 10-12 g/dL 4

The KDIGO guidelines specifically recommend maintaining ferritin >200 ng/mL and TSAT >20% to minimize ESA requirements in hemodialysis patients. 2

Monitoring Schedule

Check iron parameters:

  • Every 3 months during stable maintenance therapy 2
  • 4-8 weeks after any dose adjustment 1
  • Critical timing consideration: Ferritin remains spuriously elevated for 2-3 weeks after 100-200 mg IV iron doses 6
  • TSAT returns to baseline within 4 days 6

Avoid checking ferritin within 4 weeks of IV iron administration, as circulating iron interferes with the assay leading to falsely elevated results. 1

Formulation-Specific Dosing

Iron dextran, ferric carboxymaltose, or ferumoxytol:

  • Can be given as total dose infusion up to 1000-1500 mg 1
  • Ferric derisomaltose (FDI) is FDA-approved for doses up to 20 mg/kg, not exceeding 1500 mg 1
  • Dilute in 100 mL normal saline 1

Iron sucrose:

  • Typically given as 100 mg per dialysis session 3, 7
  • Maximum single dose 200-300 mg 7

Common Pitfalls

Functional vs. Absolute Iron Deficiency:

  • Functional deficiency: TSAT ≤20% with ferritin 100-800 ng/mL (hepcidin-mediated iron sequestration) 2
  • Absolute deficiency: Ferritin <100 ng/mL 2
  • Both require IV iron in dialysis patients 2

Inflammation confounds ferritin interpretation:

  • Ferritin is an acute phase reactant and may be elevated despite true iron deficiency 1
  • In discordant cases (high ferritin, low TSAT), the TSAT is more reliable for guiding therapy 1
  • Consider reticulocyte hemoglobin content (CHr <29 pg indicates iron deficiency) if available 8

Dosing frequency matters:

  • Monthly 200 mg is more effective than 100 mg for reducing ESA requirements 4
  • Proactive high-dose (400 mg monthly) reduces cardiovascular events compared to reactive low-dose (145 mg monthly) 3

Safety Considerations

Infection risk:

  • No increased infection rate with high-dose vs. low-dose IV iron regimens 3
  • Current guidelines do not increase bacterial infection risk 2

Test dosing:

  • Consider 25 mg test dose for iron dextran formulations 2
  • Newer formulations (ferric carboxymaltose, ferumoxytol, ferric derisomaltose) typically do not require test dosing 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Iron Therapy in Chronic Kidney Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Intravenous Iron in Patients Undergoing Maintenance Hemodialysis.

The New England journal of medicine, 2019

Guideline

Iron Supplementation Stopping Criteria

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Iron supplementation in haemodialysis--practical clinical guidelines.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 1998

Related Questions

What IV iron dose should be given to an adult on hemodialysis to raise ferritin above 200 ng/mL and maintain transferrin saturation above 20 % without exceeding ferritin 800 ng/mL?
Are there restrictions for iron infusion in patients undergoing hemodialysis (HD)?
What is the appropriate management for a patient with elevated liver enzymes and hyperferritinemia?
What is the appropriate dose of Monoferric (ferric carboxymaltose) for a 70‑year‑old bedridden obese female with chronic kidney disease, open bleeding wounds, and iron‑deficiency anemia (hemoglobin 70–80 g/L)?
What is the appropriate management for a middle-aged male patient with persistently elevated ferritin levels (less than 1000), a Transferrin Saturation (TSAT) of less than 45%, and testicular microlithiasis?
What are the possible causes of bilateral erythema and pruritus with 0.2 cm papular lesions on the palms, soles, and axillae?
What are the differential diagnoses for oropharyngeal dysphagia?
In a generally healthy adult with mildly to moderately elevated triglycerides who is not taking triglyceride‑lowering therapy, can citrus bergamot extract or berberine be used to lower triglyceride levels?
Should tadalafil be continued in a patient with pelvic‑floor hypertonicity causing pain and insomnia, or should it be discontinued in favor of pelvic‑floor physiotherapy and cognitive‑behavioural therapy for insomnia?
Which ultrasound modality is recommended to evaluate the ovaries?
Can a long‑acting muscarinic antagonist (e.g., tiotropium) be used as the sole maintenance therapy in a patient with stable mild‑to‑moderate chronic obstructive pulmonary disease and few symptoms?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.